Tuberculosis (TB) Diagnostics Market Revenue Expansion and Share Analysis 2034
Tuberculosis (TB) Diagnostics Market Revenue Expansion and Share Analysis 2034
The Tuberculosis (TB) is a contagious disorder caused by Mycobacterium tuberculosis, with the lungs being the most commonly affected site. However, the infection can also affect other parts of the body, including the brain and spine. Diagnosis plays an important role in identifying tuberculosis cases and supporting efforts to control its spread. TB can be diagnosed through different approaches, including skin tests, blood tests, sputum-based examinations, culture-based methods, and molecular diagnostic technologies.
According to Fortune Business Insights, the global tuberculosis (TB) diagnostics market size was valued at USD 2.40 billion in 2025 and is projected to grow from USD 2.53 billion in 2026 to USD 4.14 billion by 2034, exhibiting a CAGR of 6.3% during the forecast period. North America dominated the tuberculosis diagnostics market with a market share of 28.33% in 2025.
A notable trend in the tuberculosis diagnostics market is the growing interest in non-sputum-based and biomarker-driven diagnostic approaches. Conventional sputum microscopy and molecular testing remain important methods, but collecting suitable sputum samples can be difficult for children, older adults, immunocompromised individuals, and people affected by extrapulmonary tuberculosis.
As a result, diagnostic companies and researchers are developing alternative approaches based on blood, urine, oral swabs, and breath samples. Emerging technologies include host gene-expression signatures, antigen assays, and oral swab molecular tests. These approaches are intended to support earlier detection and improve access to testing among populations where conventional sample collection is challenging.
Rising Incidence of Tuberculosis in High-Burden Countries to Boost Market Growth
The increasing incidence of tuberculosis across high-burden and emerging countries is a major factor supporting the demand for diagnostic technologies. According to Fortune Business Insights, the growing patient population has increased the need for effective diagnostic technologies capable of improving the accuracy and efficiency of tuberculosis diagnosis.
The increasing availability of nucleic acid amplification tests (NAATs) and rapid molecular assays is also supporting market development. These technologies can provide faster results and improve the identification of tuberculosis, including challenging cases. Healthcare systems in high-burden countries are increasingly adopting such technologies, while healthcare agencies and government organizations are updating diagnostic guidelines and recommending advanced testing approaches.
High Cost of Advanced Diagnostic Technologies May Hamper Market Expansion
The high cost associated with advanced diagnostic technologies remains a challenge. Rapid molecular testing platforms require investment in instruments, test cartridges, calibration, maintenance, biosafety measures, and trained laboratory personnel. These requirements can make decentralized testing difficult, particularly in primary healthcare and community settings.
Recurring expenditure on diagnostic consumables can also place pressure on public healthcare budgets and limit testing volumes. Consequently, resource-constrained programs may continue to depend on less expensive microscopy-based diagnostic approaches.
Favorable Government Policies and Free Testing Programs to Create Lucrative Opportunities
Government policies and publicly funded tuberculosis screening programs are creating opportunities for market expansion. National TB control and elimination strategies increasingly emphasize early case detection, rapid molecular testing, and expanded access to diagnostic services.
Government procurement programs and investments in decentralized testing can encourage the deployment of nucleic acid amplification tests, digital chest X-ray systems, and other rapid diagnostic tools. The increasing focus on active case finding and wider access to testing can further increase diagnostic volumes among underserved and high-risk populations.
Persistent Diagnostic Gaps and Delayed Case Detection to Challenge Market Growth
Diagnostic delays continue to create challenges for the tuberculosis diagnostics market. TB symptoms can resemble those of other respiratory diseases, while certain patient groups may have difficulty producing adequate sputum samples. Limited laboratory infrastructure, shortages of trained personnel, weak sample-transport networks, and limited awareness can further delay diagnosis, particularly in rural and resource-constrained areas.
Hoffmann-La Roche Ltd (Switzerland)
BIOMÉRIEUX (France)
QIAGEN (Netherlands)
BD (U.S.)
Cepheid (Danaher) (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Abbott (U.S.)
Hologic, Inc. (U.S.)
Hain Lifescience GmbH (Germany)
Revvity (U.S.)
By Type (Culture-based Diagnostics, Sputum Smear Microscopy, Rapid Molecular Diagnostics, and Others)
By Disease Site (Pulmonary Tuberculosis and Extrapulmonary Tuberculosis)
By End-user (Diagnostic & Reference Laboratories, Hospitals, Academic & Research Institutes, and Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/tuberculosis-tb-diagnostics-market-102009
North America
North America accounted for the largest regional share of the tuberculosis diagnostics market. The region reached USD 0.68 billion in 2025. Increasing tuberculosis prevalence and the presence of established market players are supporting the regional market. The U.S. market is anticipated to reach USD 0.67 billion in 2026.
Asia Pacific
Asia Pacific is projected to be the second-largest regional market, reaching USD 0.83 billion in 2026. Improvements in healthcare infrastructure, the high burden of tuberculosis, and increasing demand for improved treatment outcomes are supporting market growth. China, Japan, and India represent important markets within the region.
Europe
Europe is projected to be the third-largest region, with the market expected to reach USD 0.45 billion in 2026. Increasing demand for rapid molecular diagnostics and initiatives by European government agencies to expand diagnostic laboratory infrastructure are supporting regional development.
The future scope of the tuberculosis (TB) diagnostics market is closely associated with the development and adoption of rapid, accurate, and accessible diagnostic technologies. The increasing focus on non-sputum testing, biomarker-based approaches, rapid molecular diagnostics, and decentralized testing is expected to shape market development.
Product innovation and research activities are also expected to influence the competitive landscape. Developments involving molecular testing, next-generation sequencing, oral-swab-based testing, and tuberculosis drug-resistance detection demonstrate the industry's focus on improving diagnostic capabilities. Government-supported testing programs, investments in diagnostic infrastructure, and increasing emphasis on early case identification are expected to provide additional opportunities for market participants through 2034.
What’s Driving Japan’s Market? Discover the Latest -Tuberculosis Diagnostics Market- Insights